NOVARTIS Company Profile

What is the competitive landscape for NOVARTIS

NOVARTIS has one hundred and eighty-eight approved drugs.

There are one hundred and twenty-six US patents protecting NOVARTIS drugs.

There are two thousand nine hundred and twenty-three patent family members on NOVARTIS drugs in sixty-six countries and five hundred and sixty-seven supplementary protection certificates in twenty countries.

Summary for NOVARTIS

International Patents:	2923
US Patents:	126
Tradenames:	156
Ingredients:	140
NDAs:	188
Drug Master File Entries:	1
Patent Litigation for NOVARTIS:	See patent lawsuits for NOVARTIS
PTAB Cases with NOVARTIS as patent owner:	See PTAB cases with NOVARTIS as patent owner

Drugs and US Patents for NOVARTIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VIJOICE	alpelisib	TABLET;ORAL	215039-001	Apr 5, 2022		RX	Yes	No	12,427,141
Novartis	TRILEPTAL	oxcarbazepine	TABLET;ORAL	021014-002	Jan 14, 2000	AB	RX	Yes	No
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-002	Jul 28, 1988		DISCN	Yes	No
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No
Novartis Pharm	TABRECTA	capmatinib hydrochloride	TABLET;ORAL	213591-001	May 6, 2020		RX	Yes	No
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No

Expired US Patents for NOVARTIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	PROMACTA KIT	eltrombopag olamine	FOR SUSPENSION;ORAL	207027-001	Aug 24, 2015	7,160,870*PED
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-001	Mar 30, 2009	7,741,338
Novartis	PROMACTA KIT	eltrombopag olamine	FOR SUSPENSION;ORAL	207027-002	Sep 27, 2018	7,795,293*PED
Novartis Pharm	AFINITOR DISPERZ	everolimus	TABLET, FOR SUSPENSION;ORAL	203985-002	Aug 29, 2012	8,617,598*PED
Novartis	TEGRETOL	carbamazepine	TABLET;ORAL	016608-001	Approved Prior to Jan 1, 1982	4,409,212
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-001	Nov 20, 2008	7,332,481*PED

Paragraph IV (Patent) Challenges for NOVARTIS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets for Oral Suspension	2 mg, 3 mg and 5 mg		2016-12-30
	Transdermal System Extended-release	13.3 mg/24 hr		2013-01-22
	Tablets	2.5 mg, 5 mg, and 7.5 mg		2014-12-10
	Tablets	90 mg and 360 mg		2015-10-19
	Tablets	100 mg and 400 mg		2007-03-12
	Tablets	320 mg/12.5 mg and 320 mg/25 mg		2007-02-07
	Tablets	180 mg		2016-04-28
	Capsules	20 mg and 40 mg		2008-06-04
	Tablets	5 mg/320 mg		2007-11-26
	Injection	0.8 mg (base) /mL		2008-06-11
	Tablets	10 mg/320 mg		2007-11-09
	Ophthalmic Solution	0.003%		2015-12-30
	Tablets	10 mg/12.5 mg/160 mg		2009-10-22
	Tablets	150 mg, 300 mg and 600 mg		2006-05-05
	Tablets	50 mg and 75 mg		2014-01-07
	Delayed-release Tablets	360 mg		2009-02-02
	Tablets	60 mg and 120 mg		2004-12-22
	Tablets	40 mg, 80 mg,160 mg		2004-12-28
	Extended-release Tablets	100 mg		2005-12-30
	Tablets	0.25 mg, 0.5 mg, and 0.75 mg		2013-09-30
	Oral Solution	2 mg/mL		2004-11-05
	Tablets	10 mg		2014-06-18
	Tablets	2.5 mg		2006-03-02
	Capsules	0.5 mg		2014-09-22
	Tablets	80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg		2005-12-02
	Tablets	180 mg		2015-10-23
	Capsules	400 mg		2014-01-24
	Tablets	5 mg/160 mg		2007-10-22
	Capsules	150 mg and 200 mg		2013-01-29
	Tablets	10 mg/160 mg		2007-10-01
	Injection	4 mg/100 mg, 100 mL vial		2012-01-31
	Tablets	5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 m		2009-09-14
	Nasal Spray	0.665 mg/ Spray		2009-06-29
	Tablets	125 mg, 250 mg and 500 mg		2004-12-28
	Oral Suspension	300 mg/5 mL		2006-12-26
	Tablets	12.5 mg and 25 mg		2014-02-04
	Delayed-release Tablets	180 mg		2009-06-04
	Tablets	250 mg		2011-03-14
	Capsules	1.5 mg, 3 mg, 4.5 mg and 6 mg		2004-04-21
	Tablets	125 mg, 250 mg, and 500 mg		2011-10-28

International Patents for NOVARTIS Drugs

Country	Patent Number	Estimated Expiration
Spain	2643016
Morocco	27668
Mexico	2015011962
Austria	535233
World Intellectual Property Organization (WIPO)	2015181739
Spain	2344700

Supplementary Protection Certificates for NOVARTIS Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1507558	18/2012	Austria		PRODUCT NAME: ALISKIREN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND HYDROCHLORTHIAZID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 - 060 20111122; FIRST REGISTRATION: LI 61678 01-61678 05 20110705
2099447	301209	Netherlands		PRODUCT NAME: CAPMATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/22/1650 20220621
0503785	C300375	Netherlands		PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
0503785	91330	Luxembourg		CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
2929031	SPC/GB21/031	United Kingdom		PRODUCT NAME: INCLISIRAN; REGISTERED: UK EU/1/20/1494(NI) 20201210; UK PLGB 00101/1202 20201210
1761528	132014902315090	Italy		PRODUCT NAME: TRAMETINIB, OPZIONALMENTE NELLA FORMA DI UN SUO SALE, IDRATO O SOLVATO FARMACEUTICAMENTE ACCETTABILE(MEKINIST); AUTHORISATION NUMBER(S) AND DATE(S): EU/I/14/931/001-006, 20140702

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Nova Labs Ltd
• Novadaq Tech
• Novartis
• Novartis Pharm
• Novartis Pharms
• Novartis Pharms Corp

Pharmaceutical Competitive Landscape Analysis: NOVARTIS – Market Position, Strengths & Strategic Insights

Last updated: October 15, 2025

Introduction

Novartis AG stands as a global leader in the pharmaceutical industry, renowned for its innovation, extensive portfolio, and strategic market positioning. Operating across diverse therapeutic areas, including oncology, cardiovascular, immunology, and ophthalmology, Novartis has cemented itself as a formidable competitor amid evolving industry dynamics influenced by patent cliffs, regulatory shifts, and biotechnological advancements. This detailed analysis examines Novartis’s market positioning, core strengths, and strategic initiatives that sustain its competitive edge, providing essential insights for stakeholders navigating the complex pharmaceutical landscape.

Market Position of Novartis

Global Footprint and Market Share

Novartis operates in over 155 countries, with a substantial footprint across North America, Europe, Asia, and emerging markets. The company's revenue in 2022 was approximately USD 51.6 billion, placing it among the top-tier pharmaceuticals globally [1]. Its key therapeutic areas—oncology, ophthalmology, and generics—contribute significantly to its revenue streams, with targeted investments in innovative treatments positioning Novartis as a leader, especially in oncology.

In the global pharmaceutical ranking, Novartis consistently ranks within the top three companies by revenue, trailing only behind Pfizer and Roche in some metrics [2]. Its strategic focus on high-growth areas like immuno-oncology and gene therapies aligns with prevailing industry trends, enhancing its market share.

Competitive Dynamics

Novartis’s primary competitors include Roche, Pfizer, Johnson & Johnson, and Merck & Co. The company’s differentiation stems from a strong pipeline of innovative therapies, notably in cell and gene therapies (e.g., Kymriah and Leqvio). However, patent expirations of blockbuster drugs—such as the oncology treatment Gleevec—pose ongoing risks, demanding continuous R&D investment.

With the rising prominence of biosimilars and generics, especially in Europe and India, Novartis faces competitive pressure to defend its proprietary drugs while expanding its biosimilar portfolio. Strategic acquisitions, such as the purchase of the ophthalmology business from Alcon (previously part of Novartis) and recent investments in digital health, demonstrate adaptive strategies to maintain competitive relevance.

Strengths of Novartis

Robust Innovation Pipeline

Novartis invests approximately 20% of its revenue into R&D annually, translating to over USD 10 billion committed to discovering new medicines [1]. Its pipeline includes promising candidates in oncology (e.g., asciminib for CML), ophthalmology (e.g., Beovu for macular degeneration), and rare diseases. The company also fosters collaborations with biotech firms and academic institutions, securing early access to groundbreaking therapies.

Diverse Therapeutic Portfolio

The company’s diversified portfolio mitigates risks associated with dependence on single products. Oncology accounts for about 36% of revenue, while ophthalmology and generic medicines contribute significantly, providing a balanced revenue base that cushions against patent cliff impacts.

Strategic Acquisitions and Partnerships

Novartis’s strategic acquisitions enhance its pipeline and market presence. The acquisition of AveXis in 2018, specializing in gene therapies for spinal muscular atrophy, exemplifies this approach. Additionally, partnerships with digital health accelerators, such as DataBricks and Health2047, augment its capabilities in personalized medicine and real-world evidence generation.

Technological Advancements and Digital Transformation

Novartis leverages digital technologies, including artificial intelligence (AI) and machine learning, to optimize drug discovery, clinical trials, and patient engagement. Its digital initiatives improve R&D efficiency and foster patient-centric approaches, crucial in a competitive landscape.

Market Access and Regulatory Expertise

The company has demonstrated adeptness in navigating complex regulatory environments, securing approvals from agencies such as the FDA and EMA promptly. Its refined market access strategies further enhance uptake and reimbursement pathways, contributing to a sustained revenue flow.

Strategic Insights and Future Outlook

Emphasis on Gene and Cell Therapy Innovation

Novartis’s sizeable investment in gene and cell therapy R&D positions it at the forefront of personalized medicine. Its iterative development of therapies like Kymriah and newer candidates like CAR-T therapies targets high unmet medical needs, offering substantial growth prospects as these modalities gain regulatory approval worldwide.

Focus on Digital Health and Real-World Evidence

Expanding digital health initiatives allows Novartis to gather real-world evidence, improving clinical decision-making and boosting market confidence. Digital tools also enable remote patient monitoring and adherence, increasing treatment efficacy.

Expansion into Emerging Markets

Novartis aims to bolster its presence in Asia, Africa, and Latin America, regions exhibiting high growth potential due to increasing healthcare access and rising disease prevalence. Tailored pricing and local partnerships are vital to capturing these opportunities.

Risks and Challenges

Patent expirations, particularly in core oncology and hematology portfolios, threaten revenue stability. The rising influence of biosimilars necessitates aggressive intellectual property management. Moreover, pricing pressures from payers and governments worldwide require strategic adaptations to sustain profitability.

Sustainability and Corporate Responsibility

Novartis emphasizes sustainability, including initiatives to reduce environmental impact and improve global health outcomes, aligning corporate strategies with regulatory and societal expectations. These efforts foster goodwill and facilitate market access in key regions.

Conclusion

Novartis’s strategic positioning as an innovator with a diversified portfolio reinforces its competitive stature. Continued investment in gene therapies, digital health, and emerging markets, coupled with agile regulatory and partnership strategies, ensures resilience amidst sector challenges. Stakeholders should monitor Novartis’s pipeline developments and adaptation to biosimilar and patent landscape changes for informed decision-making.

---

Key Takeaways

• Novartis ranks among the top global pharmaceutical companies, driven by innovation, diversified therapy areas, and strategic acquisitions.
• Its R&D focus on personalized medicine and gene therapies offers high-growth opportunities in high unmet medical needs.
• Market expansion in emerging economies and digital health initiatives constitute vital pillars of its future growth strategy.
• Patent expirations and biosimilar competition necessitate proactive intellectual property management and portfolio diversification.
• Sustained investment in technological capabilities and partnerships enhances Novartis's competitive edge and operational efficiency.

---

FAQs

Q1: How does Novartis differentiate itself in the highly competitive oncology market?
Novartis differentiates through innovative therapies like CAR-T cell treatments (Kymriah), targeted small molecules, and a robust pipeline focusing on precision oncology, supported by substantial R&D investments and strategic collaborations.

Q2: What are the main risks facing Novartis's future growth?
Key risks include patent expirations, biosimilar competition, pricing pressures, regulatory delays, and geopolitical impacts, especially in emerging markets.

Q3: How is Novartis investing in digital health?
Novartis leverages AI, data analytics, and remote monitoring tools to optimize clinical trials, enhance patient engagement, and improve real-world evidence collection, aligning with the trend toward personalized medicine.

Q4: What strategic acquisitions have significantly impacted Novartis’s portfolio?
Notable acquisitions include AveXis (gene therapies), Alcon’s eye care division, and digital health startups, all contributing to product diversification and technological capabilities.

Q5: What is the outlook for Novartis in emerging markets?
The company aims to penetrate high-growth regions through localized pricing, strategic partnerships, and tailored product offerings, expanding access to innovative medicines amid these growing healthcare markets.

---

Sources:

1. Novartis Annual Report 2022.
2. IQVIA Pharmaceutical Market Reports 2022.